Credit Suisse’s Nektar Therapeutics NKTR Stock Holding History

Credit Suisse’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-893	Closed	-$181K	–	4093
2021 Q4	$181K	Buy	+893	New	+$194K	﹤0.01%	4298

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse's NKTR Position: Q2 2023 in Review

Credit Suisse sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 11,657 shares — an estimated $123K sold.

Credit Suisse first reported a position in NKTR in Q2 2013 and held it in 40 quarters. The position peaked at $41.7M in Q1 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Credit Suisse reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Credit Suisse sold 11,657 Nektar Therapeutics shares in Q2 2023, an estimated $123K.
Credit Suisse first reported a position in Nektar Therapeutics in Q2 2013 and held it in 40 quarters.
Credit Suisse's Nektar Therapeutics position peaked at $41.7M in Q1 2018.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.